- Home
- MTA vs ACRV Comparison
MTA vs ACRV Comparison
Compare MTA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- ACRV
- Stock Information
- Founded
- MTA 1983
- ACRV 2018
- Country
- MTA Canada
- ACRV United States
- Employees
- MTA N/A
- ACRV N/A
- Industry
- MTA
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- MTA
- ACRV Health Care
- Exchange
- MTA Nasdaq
- ACRV Nasdaq
- Market Cap
- MTA 237.9M
- ACRV 247.8M
- IPO Year
- MTA N/A
- ACRV 2022
- Fundamental
- Price
- MTA $3.08
- ACRV $6.44
- Analyst Decision
- MTA
- ACRV Strong Buy
- Analyst Count
- MTA 0
- ACRV 5
- Target Price
- MTA N/A
- ACRV $22.40
- AVG Volume (30 Days)
- MTA 394.7K
- ACRV 46.9K
- Earning Date
- MTA 11-14-2024
- ACRV 11-13-2024
- Dividend Yield
- MTA N/A
- ACRV N/A
- EPS Growth
- MTA N/A
- ACRV N/A
- EPS
- MTA N/A
- ACRV N/A
- Revenue
- MTA $5,048,000.00
- ACRV N/A
- Revenue This Year
- MTA $44.57
- ACRV N/A
- Revenue Next Year
- MTA $126.18
- ACRV N/A
- P/E Ratio
- MTA N/A
- ACRV N/A
- Revenue Growth
- MTA 28.55
- ACRV N/A
- 52 Week Low
- MTA $2.32
- ACRV $3.19
- 52 Week High
- MTA $4.08
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- MTA 41.34
- ACRV 31.95
- Support Level
- MTA $3.01
- ACRV $6.11
- Resistance Level
- MTA $3.21
- ACRV $8.35
- Average True Range (ATR)
- MTA 0.16
- ACRV 0.48
- MACD
- MTA -0.05
- ACRV -0.23
- Stochastic Oscillator
- MTA 28.33
- ACRV 12.55
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.